CED Member Update: NeuroTronik Achieved All Series A Development Milestones; Seeking Additional Investors for Series B

1 March 2016 – CED Life Science Conference – Podium Comments of Fred McCoy

Last year at this time, NeuroTronik participated in the medical technology showcase. CED invited me to share a brief update on NeuroTronik one year on. It’s a good example of medical technology innovation and company development via a team located here in North Carolina.

NeuroTronik is a development-stage, venture-backed medical technology company which is pioneering cardiac autonomic nerve stimulation (CANS) therapy to improve clinical and economic outcomes associated with hospitalizations for the treatment of Acute Heart Failure Syndrome (AHFS). Through direct control of heart rate and cardiac contractility, NeuroTronik CANS Therapy™ is designed to enhance perfusion, improve hemodynamics, and potentiate diuresis. Patients should feel better sooner, spend less time in intensive care, be able to leave the hospital sooner and drier, and be readmitted within 30 days less frequently.

NeuroTronik has now achieved all of its Series A development milestones. The signature deliverable was a Human NeuroCatheter™ Study completed in December. In that study, we demonstrated the NeuroTronik therapy in 16 patients. The results were outstanding. Thus, we’re on to a Series B Preferred Stock financing during 2016. Our current investors are solid in their support and plan participation in Series B. We’re on the road just now working to identify the right additional investors for this round. Our Series B is designed to fund the Company through CE Mark approval and into early Europe commercialization.

That’s the NeuroTronik update. This project is going very well.


Best regards,

Fred McCoy

NeuroTronik Limited

get the latest